Apollo Therapeutics Fund financial update

AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) and Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) will each contribute L10 million ($14.3 million) over the fund’s six-year life. The pharmas will receive the right of first negotiation to advance projects in which the fund invests, following an internal bidding process. Each will also contribute in-kind resources and R&D expertise. ...